RxDoctor Payments Data

Robert Wilcox, MD

Family Medicine · Waco, TXNPI 1265413140

Payments from drug & device makers

$5,602in general payments, 2019–2025

Across 236 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$543
  • AbbVie$492
  • Phathom Pharmaceuticals, Inc.$403
  • Pfizer$228
  • GSK$222
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,51098%
  • Education$922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,602 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$112,936
Medicare patients
296
Services billed
2,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$232,196
Avonex Pen (4 Pack)Interferon Beta-1a12$115,092
JardianceEmpagliflozin86$73,483
FarxigaDapagliflozin Propanediol43$40,416
EliquisApixaban33$37,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,794
RybelsusSemaglutide26$24,104
Tresiba Flextouch U-200Insulin Degludec16$18,461
JanuviaSitagliptin Phosphate21$17,347
MyrbetriqMirabegron28$16,741
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$14,884
XareltoRivaroxaban15$14,768
TrintellixVortioxetine Hydrobromide13$10,040
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,424
TradjentaLinagliptin13$7,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,255$256,300215 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr$69$86,360110 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$222$49,21478 claims
AstraZenecaFarxiga$543$40,41643 claims
PfizerEliquis$228$37,95533 claims
MerckJanuvia, Janumet Xr$90$23,69433 claims
Astellas Pharma US IncMyrbetriq$18$16,74128 claims
Johnson & JohnsonXarelto$66$14,76815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$58$10,04013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →